The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.
 
Van K. Morris
Consulting or Advisory Role - Incyte; Novartis; Regeneron
Research Funding - Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Pfizer (Inst); Redx Pharma (Inst); Sumitomo Pharma Oncology (Inst)
 
Katherine A. Guthrie
No Relationships to Disclose
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; Navire; Xilis
Consulting or Advisory Role - Abbvie; Accademia Nazionale Di Medicina (ACCMED); Amal Therapeutics; Amgen; AstraZeneca/MedImmune; AVEO; Bayer Health; Bicara Therapeutics; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Cardiff Oncology; Carina Biotech; CureTeq; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Foundation Medicine; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Harbinger Oncology, Inc; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; NeoGenomics Laboratories; Novartis; Numab; Ono Pharmaceutical; Pfizer; Redx Pharma; Repare Therapeutics; Replimune; Roche; Sanofi; Servier; Tachyon Therapeutics; Taiho Pharmaceutical; Takeda; Tempus; Xilis; Zentalis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
 
Rimini Breakstone
No Relationships to Disclose
 
Thomas Benjamin Karasic
Honoraria - AstraZeneca/MedImmune; Elevar Therapeutics; Incyte; Ipsen; Pfizer; Taiho Oncology
Consulting or Advisory Role - Incyte; Nucorion Pharmaceuticals
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); H3 Biomedicine (Inst); Incyte (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst); Tempest Therapeutics (Inst); Totus Medicines (Inst); Xencor (Inst)
 
Zishuo Ian Hu
No Relationships to Disclose
 
Sarah Colby
No Relationships to Disclose
 
Marwan Fakih
Honoraria - Amgen
Consulting or Advisory Role - Bayer; BMS; Eisai; Merck; Mirati Therapeutics; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Research Funding - Agenus (Inst); Roche/Genentech (Inst); Verastem (Inst)
 
Sepideh Gholami
Consulting or Advisory Role - QED Therapeutics
Speakers' Bureau - Helsinn Therapeutics
 
Philip Jordan Gold
No Relationships to Disclose
 
E. Gabriela Chiorean
Consulting or Advisory Role - Astellas Pharma; Axiom Healthcare Strategies; Bayer; Bristol-Myers Squibb/Celgene; Cardiff Oncology; Foundation Medicine; G1 Therapeutics; IgM Biosciences; Ipsen; Merck; Merus; Novartis; Pfizer; Regeneron; Stemline Therapeutics
Research Funding - AADi (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Erasca, Inc; FibroGen (Inst); Gilead/Forty Seven; Lonza (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis; Rafael Pharmaceuticals (Inst); Roche (Inst)
Travel, Accommodations, Expenses - G1 Therapeutics
 
Philip A. Philip
Honoraria - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb/Medarex; Celgene; Daiichi Sankyo/Astra Zeneca; Guardant Health; Guardant Health; incyte; Ipsen; Merck; Rafael Pharmaceuticals; SynCoreBio; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Bayer; Bristol-Myers Squibb/Medarex; Celgene; Incyte; Ipsen; Novartis
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); merus (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst)
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals